Dodangi 2011.
| Methods | A 6 ‐week parallel trial with 2 arms:
|
|
| Participants | Number of participants screened: 34 Number of participants included: 34 Number of participants randomised to methylphenidate: not stated Number of participants followed up: 15 in the methylphenidate group Number of withdrawals: not stated Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: range 11‐18 years old IQ: not stated Sex: not stated Methylphenidate‐naïve: not stated Ethnicity: not stated Country: Iran Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria Not stated |
|
| Interventions | Methylphenidate type: immediate release Methylphenidate dosage: not stated Administration schedule: not stated Duration of intervention: 6 weeks Treatment compliance: not stated |
|
| Outcomes |
Non‐serious adverse events: Children Depressive Inventory (CDI) measured at the end of the trial Revised Children's Manifest Anxiety Scale (RCMAS) at the end of the trial Drug side effects evaluated each 2 weeks during the study |
|
| Notes | Sample calculation: not stated Any withdrawals due to adverse events: yes, 3 gastrointestinal symptoms and 1 mania Ethics approval: not stated Funding/vested interests: not stated Key conclusions of the study authors: our study showed that duloxetine may be as effective as methylphenidate in treatment of ADHD in adolescents. Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information regarding side effects received from the author in November 2013 (Dodangi 2013 [pers comm]) |
|